Pharmacodynamics of the agents used for the treatment of erectile dysfunction.

Erectile dysfunction (ED) is one of the most common complaints encountered by the practicing urologist, particularly when treating older men. The last 20 years have represented a pivotal time in the treatment of ED. Areas covered: Several pharmacologic agents have been approved by regulatory agencies, including phosphodiesterase type 5 (PDE5) inhibitors, intraurethral suppositories, and vasoactive injectable agents. This review will focus on the pharmacodynamic properties of these agents and the clinical consequences of those properties. Expert opinion: The decision on which agent to use should be individualized and based on the patient's goals and likelihood of success with the chosen treatment. The selection is also often driven by side-effect profiles that can be minimized by understanding the interplay between the individual patient and the medication. A thorough knowledge of the metabolism and pharmacologic properties of the available therapies will aid the urologist in selecting an individualized treatment plan for each patient.